The GOLD Podcast: Weekly Pharma Insights EMJ

For this week’s GOLD nugget, Helena highlights not one but two of GOLD’s previous guests from the world of Medical Affairs: Luca Dezzani, Vice President, Oncology Medical Affairs, Johnson & Johnson, and Luisa Luciani-Silverman, US Medical Head of Immuno-Oncology, AstraZeneca. They explore the potential value that can come from collaborating with different industries and some tips for measuring the value of medical affairs – it’s not one to be missed!
 
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Luca’s full episode: https://www.emg-gold.com/post/podcast-medical-affairs-evolution-and-the-future-for-msls
Luisa’s full episode: https://www.emg-gold.com/post/podcast-real-world-evidence-the-metrics-of-medical-affairs-and-tiktok-marketing
The Leap from Medicine to Medical Affairs: https://www.emg-gold.com/post/the-leap-from-medicine-to-medical-affairs

The GOLD Podcast may be on a break, but Helena is still here to provide you with some great insights – or GOLD Nuggets, if you will – from key opinion leaders in the pharmaceutical industry. In this special episode, she looks back at the very first episode of Season 2 which featured Judy Stewart, Senior Vice President and Head of US Vaccines at GSK. Helena considers some of the gold nuggets that Judy shared, including insights on both the vaccine industry and her approach to leadership.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
 
Judy's full podcast episode: https://www.emg-gold.com/post/vaccines-leadership-and-blockchain
Judy's Catalyst interview https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases
GSK warns against routine vaccine complacency https://www.emg-gold.com/post/gsk-warns-against-routine-vaccine-complacency
Haleon demerger completed by GSK https://www.emg-gold.com/post/haleon-demerger-completed-by-gsk

As Helena and Marc wrap up this season, they’re joined by Mike Watson, Chief Executive Officer of Mevox – a company committed to bringing vaccine technology into the 21st century.
 
Mike discusses the importance of developing new measles, mumps and rubella (MMR) vaccines, Mevox’s success so far in achieving this ambition – reaching series B funding – and its future trajectory, how COVID-19 will impact the future of vaccine development, along with a whole host of other fascinating insights. As Helena’s favourite interview of Season 2, it’s not one to be missed!
 
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
The return of the vaccines https://www.emg-gold.com/post/the-return-of-the-vaccines
Routine vaccinations: road to recovery https://www.emg-gold.com/post/routine-vaccinations-road-to-recovery
A heyday for mRNA https://www.emg-gold.com/post/a-heyday-for-mrna
Moderna set to bring mRNA innovation to UK https://www.emg-gold.com/post/moderna-set-to-bring-mrna-innovation-to-uk
GSK warns against vaccine complacency https://www.emg-gold.com/post/gsk-warns-against-routine-vaccine-complacency

This week, Claire Gillis, CEO, VMLY&R Health joins Helena and Marc on the airwaves to discuss the health and pharma highlights from the recent Cannes Lions International Festival, including the power of technology, how to spend smart on campaigns and her top moment from the festival this year.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Talking to Claire Gillis https://www.emg-gold.com/post/podcast-talking-to-claire-gillis
Innovative tech, pharma supply chains and more https://www.emg-gold.com/post/podcast-innovative-tech-pharma-supply-chains-and-more
Spoonful of technology https://www.emg-gold.com/post/spoonful-of-technology-5
Cardiovascular catalyst launched by Novartis https://www.emg-gold.com/post/cardiovascular-catalyst-launched-by-novartis

In an interview double bill, Helena and Marc are joined two fantastic guests from the worlds of pharma marketing and commercial affairs. Michele Manto, Chief Commercial Officer, Galapagos, shares his thoughts on the differences in leading a large pharma company and an agile biotech, amongst other exciting topics, while Robert Grimm, Digital Marketing and Transformation Manager, Novo Nordisk, talks all things marketing with insights into developing campaigns.
 
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: 
 
A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech 
Time to turn to TikTok https://www.emg-gold.com/post/time-to-turn-to-tiktok 
Bridging the digital health divide https://www.emg-gold.com/post/bridging-the-digital-health-divide
The driving seat of organisational change https://www.emg-gold.com/post/the-driving-seat-of-organisational-change 

In this episode, GOLD is joined by recent catalyst interviewee Claus Zieler, President of Established Markets, Astellas, who discusses crisis management, the importance of leaders in shaping company culture, the innovation he is most excited about, and much more.
 
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
 
Claus Zieler on leadership https://www.emg-gold.com/post/claus-zieler-on-leadership
 
Reverse mentoring: a how-to guide https://www.emg-gold.com/post/reverse-mentoring-a-how-to-guide
 
Supporting patients in a war zone https://www.emg-gold.com/post/supporting-patients-in-a-war-zone
 
The hard sell of cell and gene therapies https://www.emg-gold.com/post/the-hard-sell-of-cell-and-gene-therapies